Therapy for acute myelogenous leukemia can be complicated by alloimmunization to histocompatibility antigens (HLA), with resultant refractoriness to platelet transfusions. Autologous peripheral blood or bone marrow stem cell transplantation (referred here collectively as 'autoBMT') is emerging as a standard consolidative strategy in acute myelogenous leukemia (AML). We had noted life-threatening bleeding associated with platelet transfusion refractoriness following autoBMT; we therefore retrospectively analyzed 39 AML patients for this complication following BMT. All patients received high-dose chemoradiotherapy, followed by infusion of allogeneic sibling donor (n = 12, alloBMT) or autologous (n = 27, autoBMT) stem cells. HLA alloimmunization was assessed if patients were suspected of immune refractoriness to random donor platelet transfusions. Within 100 days of stem cell infusion, one of three alloBMT and six of 12 autoBMT recipients tested were HLA alloimmunized (not statistically significant, NS). Five of six HLA alloimmunized autoBMT patients experienced delayed bleeding, which contributed to their demise while still in remission (P Ͻ 0.001). Increased platelet requirements in HLA alloimmunized autoBMT recipients were observed between days 61 and 100 post-BMT, at a median of 211 platelet transfusions vs 0 in non-alloimmunized autoBMT patients (P Ͻ 0.01) and 17 in alloBMT patients. Our data suggest that platelet transfusion refractoriness, when associated with HLA alloimmunization, is a risk factor for increased platelet transfusion requirements, delayed bleeding, and poor outcome following autoBMT for AML. Bone Marrow Transplantation (2000) 26, 315-320.
Modern therapy for acute myelogenous leukemia (AML), while still in evolution, typically includes an anthracyclinebased induction followed by aggressive consolidation. Patients in a complete remission (CR) of their AML after induction can undergo consolidative therapy with chemotherapy alone or with high-dose chemoradiotherapy followed by infusion of autologous or allogeneic stem cells (here referred to as 'autoBMT' and 'alloBMT' respectively), resulting in 45 to 55% long-term disease-free survival. [1] [2] [3] Patients who are candidates for high-dose consolidation and/or are too old to undergo allogeneic transplantation and have high-risk AML without an HLAmatched sibling or unrelated donor at the time of relapse may undergo autoBMT. In patients with AML, this procedure can be complicated by relapse or poor graft function. 4, 5 Relapse has been reported to be reduced by in vitro purging techniques, with associated prolonged post-transplant pancytopenia (with concomitant prolonged transfusion requirements), and the impact of in vitro purging on overall survival in autoBMT for AML remains unclear. 6 Refractoriness to platelet transfusions is thought to be mediated by immune as well as non-immune mechanisms; between 20 and 70% of multi-transfused patients undergoing conventional chemotherapy for AML can become refractory to platelet transfusions. [7] [8] [9] Patients with AML have a 10 to 15% risk of developing HLA alloantibodies, with an associated increased risk of platelet transfusion refractoriness, during conventional induction chemotherapy. 10 Platelets express HLA class I antigens. Patients who have had earlier exposure to allogeneic HLA class I antigens from prior transfusions or prior pregnancy are at increased risk for HLA alloimmunization, in which antibodies develop against HLA antigens.
11 Members of minority population groups, with HLA phenotypes that are not well represented in the regional donor pool, are also at a higher risk for HLA alloimmunization following transfusions from ABO-matched donors. Non-immune mechanisms of platelet transfusion refractoriness include fever, infection, hemorrhage, DIC, splenomegaly and exposure to medications such as antibiotics and antifungal agents. 7 Autologous BMT is associated with an extended period of thrombocytopenia and transfusion dependence, and we speculated that platelet refractoriness could have a measurable adverse clinical impact following BMT. To assess this, we examined the records of patients who had undergone transplantation for AML at our institution, reviewing platelet transfusion refractoriness, serologically documented HLA alloimmunization, and bleeding episodes in the first 100 days following BMT.
Materials and methods

Patients
We performed retrospective reviews of charts and transfusion records from consecutive adult AML patients who had undergone autologous BMT at the University of Minnesota between 1993 and 1997. This group of 27 was compared with 12 patients who had undergone allogeneic transplantation from HLA-matched related donors. All patients were given myeloablative preparative therapy with high-dose cytoxan (at 60 mg/kg/day for 2 days, with a total dose of 120 mg/kg) and total body irradiation (TBI, at 165 cGy twice a day for 4 days, or 1320 cGy total). This regimen was followed by infusion of unpurged (n = 25) or 4-hydroperoxycyclophosphamide-purged (n = 2) autologous bone marrow (autoBMT) or allogeneic bone marrow (n = 7) or peripheral blood stem cells (n = 5) (alloBMT). The day of stem cell infusion was designated as day 0. Routine supportive care consisted of antimicrobial prophylaxis plus broad-spectrum antibiotic therapy as needed. All blood products were irradiated but were not routinely leukoreduced. Hematopoietic growth factors (G-CSF, GM-CSF, IL-3) were widely employed, but only as a routine in patients with poor graft function, ie absolute neutrophil count Ͻ0.5 × 10 9 /l, after day +28. In patients undergoing allogeneic transplantation, GVHD prophylaxis with cyclosporine and methotrexate was given.
HLA alloimmunization, diagnosis and therapy
Patients were transfused with ABO identical or, in alloBMT patients receiving a non-identical ABO transplant, ABO compatible red cells. 12 Non-leukoreduced pooled random donor platelet concentrates, given under generally accepted institutional guidelines, were used for most transfusions. The dose of platelets was one platelet concentrate per 10 kg body weight, up to a maximum of six platelet concentrates. Patients were not tested for immune platelet refractoriness during BMT unless this was clinically suspected due to poor platelet increments following transfusion. Refractoriness was assessed by checking post-transfusion platelet counts, with a 10 to 60 min post-transfusion count increment of Ͻ5 × 10 9 platelets/l deemed unsatisfactory. Corrected count increments were not routinely used. Initially, a platelet immunofluorescence (PIF) assay was used to assess platelet refractoriness. In this assay, patient serum was incubated with a panel of lymphocytes and platelets which expressed known HLA and platelet antigens; microscopic detection of fluorescence from FITC labeled goat anti-human Ig was used to measure antibodies to these antigens in patient serum. Subsequently, a solid phase ELISA assay of patient serum against affinity purified HLA-A and B antigens and platelet glycoproteins was used. All tests were performed in the blood bank at Fairview University Medical Center. During BMT, a threshold of Ͻ10 × 10 9 platelets/l was set as a trigger for prophylactic platelet transfusion in non-bleeding patients. Patients who appeared refractory to pooled random donor platelet transfusions received platelet apheresis products that were HLAmatched or crossmatch-negative (by solid phase red cell agglutination 13 ). When available, directed platelet donations from family members were utilized. In one patient, citrate treatment of platelets prior to transfusion, reported to alter HLA antigens, 14 was attempted without benefit. Patients documented serologically as having been naïve for cytomegalovirus infection (CMV negative) were given blood products that had been leukoreduced by filtration at the bedside through Pall filters (Pall, Port Washington, NY, USA). Patients were transfused to maintain hemoglobin at Ͼ8 g/dl in non-bleeding patients and Ͼ9-10 g/dl in bleeding patients. Major bleeding was defined as bleeding that required hospitalization for control. This included hematemesis or passage of maroon or melanotic stools in the gastrointestinal (GI) tract, hemorrhagic cystitis requiring continuous bladder irrigation or uterine bleeding refractory to hormonal manipulation in the genitourinary (GU) tract, and bronchoscopically proven diffuse alveolar hemorrhage (DAH) in patients with hypoxia and pulmonary infiltrates. Oro-mucosal bleeding severe enough to lead to endotracheal intubation (for airway protection) or a significant increase in red blood cell transfusion requirements were also defined as major bleeding.
Immunomodulatory therapy was attempted in some patients with persistent platelet refractoriness. Intravenous immunoglobulin (IVIG, multiple suppliers) at 2 g/kg given over 2-5 days was used in four patients. 15 Three patients were treated with plasmapheresis and Staphylococcal protein A column (Cypress Bioscience, San Diego, CA, USA) pheresis. 16, 17 Coagulation parameters were maintained in the normal range by vitamin K supplementation and fresh frozen plasma or cryoprecipitate infusions when necessary. The anti-fibrinolytic agent ⑀-amino caproic acid, Amicar (Immunex, Seattle, WA, USA), was used to promote hemostasis in some actively bleeding patients, during which time fibrinogen, fibrin degradation products and renal function were closely monitored.
Statistical analysis
For ease of comparison, the autologous BMT group was divided into two groups (Table 1) . AutoBMT-I comprised autoBMT patients who had either tested negative or had not been tested for HLA alloantibodies, presumably because they achieved adequate platelet counts with standard transfusion support throughout. Auto BMT-II comprised autoBMT patients who had tested positive for HLA alloantibodies. The Student's t-test was applied as a test of significance in differences of stem cell dose and platelet transfusion requirements between the groups. All P values are two tailed, and of a two-sample equal variance (homoscedastic) type. Fisher's exact test of significance was used to determine the significance between HLA types in the two autologous BMT groups. 
Results
Patient characteristics
Patient characteristics are given in Table 1 . Age, sex, and remission status were not statistically different between these groups, although females predominated in the HLA alloimmunized autoBMT patients (5/6). The median age of the autoBMT patients was 48 years (range 18-61) and 42 years (range 19-56) for the alloBMT. Sixteen out of 27 (60%) patients undergoing autologous BMT were female as opposed to 4/12 (34%) undergoing allogeneic BMT. Twenty (74%) autoBMT patients were in first complete remission (CR 1) of AML in the autoBMT group vs four (34%) in the alloBMT patients.
HLA alloimmunization
Twelve of 27 (44%) autologous BMT recipients were tested for HLA alloimmunization as opposed to 3/12 (25%) allogeneic BMT recipients (NS). Six of 27 (22%) autoBMT recipients (one-half of those tested) with platelet transfusion refractoriness had serologically proven HLA alloimmunization within the first 100 days following transplantation, compared with one patient, a woman, of the 12 (8%) alloBMT patients (1/3 of those tested, NS). The six alloimmunized autoBMT patients, 'autoBMT-II', were predominantly female (four of whom were parous), and the sole male was African-American. Auto BMT-II patients tended to be older, with a median age of 54 years, vs 45 years in the 21 autoBMT-I recipients and 42 years in the 12 alloBMT patients (NS). The six autoBMT-II patients received a smaller dose of hematopoietic progenitor cells as compared to the non-platelet transfusion refractory autoBMT-I patients; however, all autoBMT patients received a significantly lower number of nucleated progenitor cells when compared with the alloBMT recipients Bone Marrow Transplantation (P Ͻ 0.001). Of interest, the HLA-A1, B8 genotype was over-represented in the HLA alloimmunized autoBMT patients, at 3/6 (50%), as opposed to 2/17 (11%) in the nonplatelet refractory autoBMT patients in whom the HLA type was known (HLA not tested in four) (Fisher's exact test of significance P = 0.09 in this small group of patients). Two of six autoBMT-II patients had additional platelet specific antibodies, directed against platelet glycoprotein IIb/IIIa in one and a drug-dependent antibody (to trimethoprim-sulfamethoxazole) in another. One autologous BMT recipient, who had prolonged thrombocytopenia and was persistently refractory to platelet transfusion, did not have HLA antibodies on repeated testing.
Platelet transfusion requirements
During the first month following BMT platelet transfusion requirements were comparable in all groups, but were greatest in the HLA alloimmunized platelet transfusion refractory autoBMT-II patients (Figure 1 ). During the second and third months following transplantation, platelet transfusion requirements of the non-HLA alloimmunized autoBMT-I and alloBMT groups dropped, and the majority of patients were transfusion-free by day +100 following BMT. On the other hand, HLA alloimmunized autoBMT-II patients continued to require increasing numbers of platelet transfusions in order to maintain hemostatic competence (Figure 1 , P Ͻ 0.01 vs autoBMT-I, and P Ͻ 0.01 vs alloBMT at day +31 to day +60).
Clinical outcome
Five of six (83%) of the HLA alloimmunized autoBMT-II patients developed severe delayed hemorrhagic complications ( Table 2) . Two of these patients succumbed to their bleeding complications, and bleeding contributed significantly to the demise of an additional two patients. These four were without a sustained response from HLA-matched or cross-matched platelet transfusions, but were in clinical complete remission of AML at the time of death.
Of the two autoBMT-II patients who died as a direct result of hemorrhagic complications, one developed genitourinary bleeding more than 80 days post BMT, and was platelet-transfusion refractory despite therapy with corticosteroids, IVIG and Staphylococcal protein A column pheresis. She died on day +107 from diffuse alveolar hemorrhage. The second patient developed persistent GI and GU bleeding and also failed to respond to platelet transfusions and immunomodulatory therapy. She died at day +102. In both patients, therapy with ⑀-amino caproic acid had a modest effect at best on bleeding or on platelet transfusion requirements. Neither patient had clinical evidence of megakaryocyte engraftment at the time of death. Two additional autoBMT-II patients had persistently undetectable platelet counts in spite of HLA-and/or cross-matched platelets, given intermittently or continuously, and attempts at immunomodulation. These two patients died from multiple complications to which refractory thrombocytopenia made a major contribution. One additional patient from autoBMT-II had prolonged thrombocytopenia but responded to HLA-matched platelet transfusions and did 90 (18252) 20 (0174) 17 (0225) 185 (83219) 176 (24572)b, c
(01569)b
110 (22301) 30 (0168) 0 (0200)
aOne patient tested positive for HLA antibody.
bAutoBMT-II vs AutoBMT-I day 3160, P < 0.001; day 61100, P < 0.01. cAutoBMT-II vs AlloBMT day 3160, P < 0.01.
Figure 1
Platelet transfusion requirements following bone marrow and stem cell transplantation. Shown graphically and in tabular form are the number of platelets concentrates transfused during the indicated intervals (days 0 to +30, days +31 to +60, and days +61 to +100), following autologous (n = 27) or allogeneic (n = 12) stem cell transplantation as therapy for AML. Autologous patients are further divided, depending on whether they were platelet refractory and HLA alloimmunized (n = 6), or not (n = 21). In quantitating platelet transfusions, one apheresis unit was considered equivalent to six random donor concentrates. not develop significant bleeding complications. Of the other 21 non-platelet refractory autoBMT group I patients, six were tested for HLA alloimmunization and were negative. Only one of these six had a major hemorrhagic complication; she was platelet transfusion refractory and succumbed to pulmonary hemorrhage and GI/GU bleeding; she remained HLA antibody negative on repeated testing. In the allogeneic BMT group the only HLA alloimmunized patient developed DAH. Of two alloBMT patients who were not platelet refractory, one developed hemorrhagic cystitis late and one succumbed to a subdural hematoma and alveolar hemorrhage. The median disease-free survival (DFS) in patients with AML undergoing autoBMT was 5 months (range 3-36, n = 6) if they were platelet transfusion refractory and HLA alloimmunized. In contrast, median DFS was 26 months (range 2-72, n = 21) in patients not documented with, or suspected of, HLA alloimmunization early post BMT (P = 0.0075).
Discussion
We present a group of patients who underwent an autoBMT as therapy for AML and then developed transfusion-refractory thrombocytopenia. Half of the autoBMT patients suspected of, and tested for, immune platelet refractoriness were found to be HLA alloimmunized. These alloimmunized platelet transfusion refractory autoBMT patients needed more platelet transfusions and had an increased hemorrhagic-associated morbidity and mortality when compared with non-alloimmunized and/or non-platelet transfusion refractory patients undergoing autologous or allogeneic BMT.
AutoBMT patients received hematopoietic progenitor cells that had been previously exposed to chemotherapy in vivo (and in vitro in two patients) and at a lower cell dose than for allogeneic hematopoietic progenitor cells given to patients undergoing alloBMT. This may have had an adverse impact on graft function and may have increased the risk of prolonged pancytopenia and the need for trans-fusions, with associated HLA alloimmunization, in autoBMT patients. 6 Peripheral blood rather than bone marrow as a source of stem cells, reported to allow more rapid reconstitution of hematopoiesis for autologous transplantation in recent studies, 18 may mitigate the role that cell dose plays in prolonged platelet transfusion requirements post-autoBMT. It is not known whether HLA alloantibodies cross-react with 'self' HLA antigens and result in autoimmune graft dysfunction and thus prolong post-BMT cytopenia. Immunosuppressive therapy employed for GVHD prophylaxis in allogeneic BMT for AML may also lower the risk of immune-mediated platelet transfusion refractoriness, but our data are insufficient to answer this question.
The majority of HLA alloimmunized autoBMT patients in our study were parous females. This group is known to be at risk for HLA alloimmunization and transfusion refractoriness, 19 presumably because exposure to paternallyderived fetal HLA antigens during pregnancy induces a primary immune response that later leads to an anamnestic secondary response during subsequent platelet transfusions. This was seen in the TRAP study, 11 in which parous patients developed lymphocytotoxic HLA alloantibodies at a significantly higher rate than non-parous patients, even in the group receiving leukoreduced blood products.
Of interest, we found that the HLA-A1, B8 phenotype was over represented in the HLA alloimmunized autoBMT-II patients, when compared with the non-alloimmunized autoBMT patients (50% vs 11%). This observation, while not statistically significant, is intriguing since the HLA-A1, B8, DR3 haplotype has been associated with a variety of organ-specific autoimmune diseases, 20, 21 such as in hypocomplementemia associated with systemic lupus erythematosis. 22, 23 Historically, platelet transfusion refractoriness from HLA alloimmunization has been reported to respond poorly to therapeutic interventions, 7, 9 as we also experienced. Attempted therapeutic strategies have included transfusion of HLA matched or cross matched platelets, 7, 24 in which HLA-A and B phenotypically identical or similar donors are selected, or in which donors are tested with patient serum in order to avoid incompatibility due to clinically significant HLA and platelet-specific antibodies. In our patient population, only 2/6 HLA alloimmunized autoBMT patients responded to these directed transfusions. Perhaps unsurprisingly, given the degree of severe thrombocytopenia and mucosal injury post-BMT, we did not find ⑀-amino caproic acid to be therapeutically useful. In addition, immunomodulation with IVIG, 7, 15 plasmapheresis or Staphylococcal protein A column pheresis, 16, 17 which have been reported to have a role in the management of idiopathic thrombocytopenia or post-transfusion purpura, have not been documented to be efficacious in managing transfusion refractoriness in HLA alloimmunized patients, and were not useful in our patients.
Leukoreduced blood products from the time of diagnosis with AML were not routinely used in our patients. The standard use of leukoreduced blood products in acute leukemia, using either bedside or pre-storage leukoreduction, has been espoused. 19, 25 Multiple trials, 26, 27 such as the randomized TRAP study, 11 have shown that leukoreduction or
Bone Marrow Transplantation ultraviolet irradiation of blood products prior to transfusion significantly reduces the incidence of HLA alloimmunization and platelet transfusion refractoriness in patients undergoing therapy for AML. This suggests that use of leukoreduced blood products throughout therapy for AML may reduce platelet refractoriness following autologous BMT. Twenty-one of 27 (77%) patients did not develop platelet refractoriness during the course of their BMT, despite receiving non-leukoreduced blood products; therefore, problematic HLA alloimmunization appears in a minority of AML patients. However, our data indicate that platelet refractoriness with HLA alloimmunization can be lifethreatening when it develops in AML patients who are undergoing an autoBMT, in which case the risk of bleeding is extreme.
In our retrospective study, we are not able to determine the precise incidence of platelet refractoriness in all patients, as there was no consistent clinical threshold for assessing transfusion refractoriness. In addition, HLA alloimmunization was investigated only at the discretion of the attending physician. We cannot statistically exclude the possibility that the increase in early post-BMT mortality which we attributed to platelet transfusion refractoriness with associated HLA alloimmunization was not, instead, due to graft dysfunction, infections, etc, but this was not obvious.
We conclude that platelet refractoriness and HLA alloimmunization may be a risk factor for poor outcome from autologous BMT in AML. It is worth noting that threequarters of the autoBMT patients in our study (vs one-third of the alloBMT patients (NS)) were in first complete remission of AML at the time of transplant. Historically, certain groups of patients, such as parous women, racial minorities, and we speculate those with the HLA-1, B-8 phenotype may be at an especially high risk for HLA alloimmunization.
The poor prognosis that we describe in our small group of platelet refractory HLA alloimmunized autoBMT patients may be especially cautionary as the use of autologous BMT for consolidation in standard AML therapy increases. The need to prevent HLA alloimmunization by the use of leukoreduction during induction and subsequent therapy in AML is re-emphasized. Alternative strategies to increase cell dose at transplant and therefore shorten the duration of pancytopenia, such as the use of peripheral blood progenitor cells with hematopoietic growth factors, may reduce platelet refractory bleeding associated with HLA alloimmunization. The incidence of HLA alloimmunization and platelet refractoriness in BMT patients needs to be studied prospectively in autoBMT as well as in other stem cell transplantation strategies that have a propensity for slow engraftment, such as cord blood and unrelated donor stem cell transplants.
